Galmed Pharmaceuticals (NASDAQ:GLMD) announced its earnings results on Wednesday. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.11, Fidelity Earnings reports.
Shares of NASDAQ GLMD traded down $0.16 during mid-day trading on Friday, reaching $4.21. The company had a trading volume of 56,400 shares, compared to its average volume of 88,563. The stock’s 50 day moving average is $4.27 and its 200-day moving average is $5.73. The stock has a market capitalization of $99.83 million, a PE ratio of -7.80 and a beta of 2.86. The company has a debt-to-equity ratio of 0.01, a quick ratio of 25.69 and a current ratio of 25.69. Galmed Pharmaceuticals has a twelve month low of $3.42 and a twelve month high of $10.66.
Several brokerages have issued reports on GLMD. Zacks Investment Research downgraded shares of Galmed Pharmaceuticals from a “buy” rating to a “hold” rating and set a $4.25 target price on the stock. in a research note on Tuesday, October 29th. Cantor Fitzgerald reissued an “overweight” rating on shares of Galmed Pharmaceuticals in a research note on Friday, October 18th. Laidlaw began coverage on shares of Galmed Pharmaceuticals in a research note on Monday, July 22nd. They set a “buy” rating and a $25.00 target price on the stock. HC Wainwright reissued a “buy” rating on shares of Galmed Pharmaceuticals in a research note on Tuesday, August 6th. Finally, Maxim Group reissued a “buy” rating and set a $10.00 target price on shares of Galmed Pharmaceuticals in a research note on Thursday. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $25.71.
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.
Featured Article: Support Level
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.